MiMedx Group (NASDAQ:MDXG) Rating Lowered to Buy at StockNews.com

MiMedx Group (NASDAQ:MDXG) was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued on Wednesday.

Several other brokerages have also recently weighed in on MDXG. Lake Street Capital began coverage on shares of MiMedx Group in a research note on Thursday, March 7th. They issued a “buy” rating and a $12.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of MiMedx Group in a research note on Wednesday, May 1st. Finally, Cantor Fitzgerald began coverage on shares of MiMedx Group in a research note on Tuesday. They issued an “overweight” rating and a $11.00 price objective on the stock. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $12.00.

MiMedx Group Price Performance

Shares of NASDAQ MDXG traded up $0.04 during midday trading on Wednesday, reaching $6.82. 314,849 shares of the company were exchanged, compared to its average volume of 779,115. The stock’s 50-day moving average price is $7.17 and its 200-day moving average price is $7.62. The stock has a market cap of $1.01 billion, a P/E ratio of 15.50 and a beta of 1.99. MiMedx Group has a one year low of $5.57 and a one year high of $9.27. The company has a quick ratio of 2.71, a current ratio of 3.29 and a debt-to-equity ratio of 0.12.

MiMedx Group (NASDAQ:MDXG) last posted its earnings results on Tuesday, April 30th. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.03. The firm had revenue of $84.71 million for the quarter, compared to analysts’ expectations of $79.36 million. MiMedx Group had a net margin of 18.63% and a return on equity of 39.42%. On average, sell-side analysts anticipate that MiMedx Group will post 0.34 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MiMedx Group

Hedge funds and other institutional investors have recently bought and sold shares of the company. AJOVista LLC acquired a new position in shares of MiMedx Group during the fourth quarter valued at about $25,000. Headlands Technologies LLC acquired a new position in shares of MiMedx Group during the first quarter valued at about $27,000. Entropy Technologies LP acquired a new position in shares of MiMedx Group during the first quarter valued at about $99,000. Loudon Investment Management LLC acquired a new stake in shares of MiMedx Group in the 4th quarter worth about $105,000. Finally, KMG Fiduciary Partners LLC acquired a new stake in shares of MiMedx Group in the 4th quarter worth about $105,000. Institutional investors and hedge funds own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.